108 related articles for article (PubMed ID: 2823858)
41. Clinical and biochemical effects of an oral leukotriene biosynthesis inhibitor (MK886) in psoriasis.
de Jong EM; van Vlijmen IM; Scholte JC; Buntinx A; Friedman B; Tanaka W; van de Kerkhof PC
Skin Pharmacol; 1991; 4(4):278-85. PubMed ID: 1724166
[TBL] [Abstract][Full Text] [Related]
42. Erythrocyte membrane phosphorylation in untreated and in etretinate-treated psoriatic patients.
Kumar R; Weiss VC; West DP; Chiero LA
Br J Dermatol; 1983 Sep; 109(3):277-86. PubMed ID: 6615715
[TBL] [Abstract][Full Text] [Related]
43. Electrophoretic mobility of polymorphonuclear leukocytes response to scale extracts from psoriasis vulgaris.
Higuchi M
J Dermatol; 1988 Oct; 15(5):367-72. PubMed ID: 3065379
[No Abstract] [Full Text] [Related]
44. [Unusual side effects in patients with psoriatic erythroderma treated with etretinate (RO 10-9359)].
Castel T; Castro J; Lecha M; Mascaró JM
Med Cutan Ibero Lat Am; 1986; 14(2):83-6. PubMed ID: 2943953
[TBL] [Abstract][Full Text] [Related]
45. Production of intraepidermal microabscesses by topical application of leukotriene B4.
Camp R; Jones RR; Brain S; Woollard P; Greaves M
J Invest Dermatol; 1984 Feb; 82(2):202-4. PubMed ID: 6319504
[TBL] [Abstract][Full Text] [Related]
46. Distribution of skin-derived antileucoproteases (SKALP) in the marginal zone of the spreading psoriatic lesion.
Van de Kerkhof PC; Kuppens LH; Van Vlijmen Y; Schalkwijk J
Br J Dermatol; 1991 Jan; 124(1):10-2. PubMed ID: 1847066
[TBL] [Abstract][Full Text] [Related]
47. Treatment of psoriatic arthropathy with etretinate: a two-year follow-up.
Chieregato GC; Leoni A
Acta Derm Venereol; 1986; 66(4):321-4. PubMed ID: 2430403
[TBL] [Abstract][Full Text] [Related]
48. Effect of the leukotriene B4 receptor antagonist SC-41930 on colonic inflammation in rat, guinea pig and rabbit.
Fretland DJ; Widomski D; Tsai BS; Zemaitis JM; Levin S; Djuric SW; Shone RL; Gaginella TS
J Pharmacol Exp Ther; 1990 Nov; 255(2):572-6. PubMed ID: 2173749
[TBL] [Abstract][Full Text] [Related]
49. The dynamics of the response of normal skin to single and multiple epicutaneous leukotriene B4 applications analysed by three-colour flow cytometry.
Glade CP; Botermans RJ; van Erp PE; van de Kerkhof PC
Acta Derm Venereol; 1995 Nov; 75(6):437-41. PubMed ID: 8651019
[TBL] [Abstract][Full Text] [Related]
50. Etretinate therapy improves psoriasis but elevates serum lipids.
Cowart VS
JAMA; 1982 May; 247(19):2647-8. PubMed ID: 7077753
[No Abstract] [Full Text] [Related]
51. Application of leukotriene B4 and reflectance confocal microscopy as a noninvasive in vivo model to study the dynamics of skin inflammation.
Peppelman M; Wolberink EA; Gerritsen MJ; van de Kerkhof PC; van Erp PE
Skin Res Technol; 2015 May; 21(2):232-40. PubMed ID: 25156913
[TBL] [Abstract][Full Text] [Related]
52. Effect of etretinate on peripheral T lymphocytes in psoriatic patients before, during and after 6 months of therapy.
David M; Shohat B; Hodak E; Sandbank M
Dermatologica; 1990; 180(2):86-9. PubMed ID: 2138096
[TBL] [Abstract][Full Text] [Related]
53. Leukotriene formation by bovine polymorphonuclear leukocytes.
Walstra P; Verhagen J; Veldink GA; Vliegenthart JF
Biochim Biophys Acta; 1984 Oct; 795(3):499-503. PubMed ID: 6089908
[TBL] [Abstract][Full Text] [Related]
54. Superoxide production of human polymorphonuclear leukocytes stimulated by leukotriene B4.
Sumimoto H; Takeshige K; Minakami S
Biochim Biophys Acta; 1984 Apr; 803(4):271-7. PubMed ID: 6322859
[TBL] [Abstract][Full Text] [Related]
55. Effects of systemic etretinate treatment on natural cytotoxicity, immune angiogenesis and neutrophil adherence in patients with various forms of psoriasis.
Majewski S; Wolska H; Jabłońska S; Wasik M
Arch Immunol Ther Exp (Warsz); 1989; 37(3-4):459-64. PubMed ID: 2484150
[TBL] [Abstract][Full Text] [Related]
56. Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders.
Ward A; Brogden RN; Heel RC; Speight TM; Avery GS
Drugs; 1983 Jul; 26(1):9-43. PubMed ID: 6224672
[TBL] [Abstract][Full Text] [Related]
57. Effect of etretinate on chemotaxis of neutrophils from patients with pustular and vulgar psoriasis.
Pigatto PD; Riva F; Altomare GF; Brugo AM; Morandotti A; Finzi AF
J Invest Dermatol; 1983 Nov; 81(5):418-9. PubMed ID: 6631053
[TBL] [Abstract][Full Text] [Related]
58. [Clinical experience with etretinate (Tigason) in 26 patients with psoriasis].
Gajardo J
Rev Med Chil; 1989 May; 117(5):516-22. PubMed ID: 2519162
[TBL] [Abstract][Full Text] [Related]
59. Tigason (etretinate) treatment in psoriatic arthritis.
Ciompi ML; Bazzichi L; Marotta G; Pasero G
Int J Tissue React; 1988; 10(1):25-7. PubMed ID: 3397251
[TBL] [Abstract][Full Text] [Related]
60. [Treatment of therapy resistant forms of psoriasis with etretinate. Case report].
Taube KM; Wozniak KD
Dermatol Monatsschr; 1988; 174(7):399-406. PubMed ID: 3169325
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
